石藥集團(01093.HK):JAK-SyK雙靶點抑制劑“SYHX1901”獲批臨牀試驗
格隆匯 3 月 16日丨石藥集團(01093.HK)公佈,集團開發的“SYHX1901”已獲得國家藥品監督管理局批准,可開展於中國的臨牀研究。該產品在國內外已提交多件專利申請。
SYHX1901作為雙靶點抑制劑,對JAK和SyK激酶各亞型均有較強的抑制活性,在自身免疫相關性疾病方面具有廣譜開發潛力。此次獲批的臨牀適應症為類風濕性關節炎(RA)和系統性紅斑狼瘡(SLE)。臨牀前研究顯示,該產品藥效靶點選擇性高,可顯著改善SLE皮膚病變,降低關節炎指數評分,具有優異的體內外活性和良好的安全性,極有希望在臨牀研究中展現出良好的類風濕性關節炎(RA)和系統性紅斑狼瘡(SLE)治療效果。
基於良好的非臨牀研究結果,集團將全力以赴推進該產品的臨牀研究工作,力爭該產品儘快上市,以造福全球患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.